We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
-0.76%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$185M
AUM Growth
+$125M
Cap. Flow
+$127M
Cap. Flow %
69.01%
Top 10 Hldgs %
67.37%
Holding
37
New
12
Increased
18
Reduced
–
Closed
7

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$16M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.1M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$13.1M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$10.7M
5
INGN icon
Inogen
INGN
+$10.5M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$3.4M
2
ILMN icon
Illumina
ILMN
+$2.58M
3
HRTX icon
Heron Therapeutics
HRTX
+$1.66M
4
PEN icon
Penumbra
PEN
+$1.65M
5
CVS icon
CVS Health
CVS
+$1.02M

Sector Composition

Rank Sector Weight
1 Healthcare 89.71%
2 Industrials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
26
Adaptive Biotechnologies
ADPT
$3.97B
$1.09M 0.59%
+22,500
New +$997K
ABBV icon
27
AbbVie
ABBV
$435B
$1.05M 0.57%
+14,406
New +$1.13M
ATRS
28
DELISTED
Antares Pharma, Inc.
ATRS
$906K 0.49%
+275,425
New +$797K
HMSY
29
DELISTED
HMS Holdings Corp.
HMSY
$829K 0.45%
+25,598
New +$783K
ASND icon
30
Ascendis Pharma A/S
ASND
$16.8B
$438K 0.24%
+3,800
New +$455K
ALKS icon
31
Alkermes
ALKS
$8.25B
– –
-27,673
Closed -$1.01M
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-8,754
Closed -$818K
CVS icon
33
CVS Health
CVS
$122B
– –
-28,680
Closed -$1.02M
HRTX icon
34
Heron Therapeutics
HRTX
$92.9M
– –
-67,909
Closed -$1.66M
ILMN icon
35
Illumina
ILMN
$28.4B
– –
-8,551
Closed -$2.58M
PEN icon
36
Penumbra
PEN
$12.8B
– –
-11,254
Closed -$1.65M
AERI
37
DELISTED
Aerie Pharmaceuticals
AERI
– –
-71,675
Closed -$3.4M
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Asymmetry Capital Management held 37 positions worth $185M, up 209% from $59.8M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Asymmetry Capital Management deployed $127M of net new capital in Q2 2019, opening 12 new positions and adding to 18 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 176,325 shares worth $15.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 83% a quarter earlier, followed by Industrials.

On the sell side, the most notable exit was Aerie Pharmaceuticals, an estimated $3.4M sold.

  • Asymmetry Capital Management's largest Q2 2019 buy was BioMarin Pharmaceuticals: 176,325 shares worth $15.1M.
  • Asymmetry Capital Management added most to Insmed in Q2 2019, an estimated $16M increase.
  • Asymmetry Capital Management fully exited Aerie Pharmaceuticals in Q2 2019, selling an estimated $3.4M.
  • Asymmetry Capital Management's ten largest holdings make up 67% of its $185M portfolio in Q2 2019.
  • Asymmetry Capital Management opened 12 new positions and closed 7 in Q2 2019.
  • Asymmetry Capital Management's portfolio value rose 209% quarter-over-quarter to $185M.

Based on Asymmetry Capital Management's 13F filing for Q2 2019, filed 7 Aug 2019.